RT Journal
A1 Banerjee AK
T1 PHarmacists are key to enhancing benefit risk for medicines
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2009
FD October 12
VO 169
IS 18
SP 1718
OP 1725
DO 10.1001/archinternmed.2009.345
UL http://dx.doi.org/10.1001/archinternmed.2009.345
AB 
The timely article by Murray et al1 prompts me to write. We have produced nearly 30 risk minimization plans to permit the safer use of medicines by patients and to enhance the benefit to risk ratio.2 A key part of such plans, which are now enshrined in the United States under the Food and Drug Administration Amendments Act of 2007 (Pub L No. 110-85), within Risk Evaluation and Mitigation Strategies (REMS) and Risk Minimisation Action Plans, and also the Risk Management Plan of the European Medical Evaluation Agency (EMEA) in the European Union, are measures to minimize the effect of any identified and potential risks.